Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy
We describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy. She tolerated 13 cycles of chemotherapy without any significant hematological side effects, but after the 14th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/4314797 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567122794905600 |
|---|---|
| author | Eric L. Tam Padma L. Draksharam Jennifer A. Park Gurinder S. Sidhu |
| author_facet | Eric L. Tam Padma L. Draksharam Jennifer A. Park Gurinder S. Sidhu |
| author_sort | Eric L. Tam |
| collection | DOAJ |
| description | We describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy. She tolerated 13 cycles of chemotherapy without any significant hematological side effects, but after the 14th cycle, she developed melena and was admitted for severe thrombocytopenia. After supportive care, the platelet counts rapidly improved to 76,000/μL. Upon initiation of FOLFIRI and cetuximab chemotherapy, she again developed rectal bleeding and severe thrombocytopenia with a platelet count of 6000/μL. Lab testing was positive for oxaliplatin and irinotecan drug-dependent platelet antibodies on flow cytometry assay. Drug-induced thrombocytopenia (DITP) is associated with several classes of drugs with several proposed underlying mechanisms. Prospective studies are needed to further address different mechanisms of drug-induced thrombocytopenia. |
| format | Article |
| id | doaj-art-b38149500d0946c0b42ad21dcf88108b |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-b38149500d0946c0b42ad21dcf88108b2025-02-03T01:02:20ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/43147974314797Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan TherapyEric L. Tam0Padma L. Draksharam1Jennifer A. Park2Gurinder S. Sidhu3Department of Medicine, Division of Hematology and Oncology, State University of New York Downstate Medical Center, Brooklyn, USADepartment of Medicine, Division of Hematology and Oncology, State University of New York Downstate Medical Center, Brooklyn, USADepartment of Medicine, Division of Hematology and Oncology, State University of New York Downstate Medical Center, Brooklyn, USADepartment of Medicine, Division of Hematology and Oncology, State University of New York Downstate Medical Center, Brooklyn, USAWe describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy. She tolerated 13 cycles of chemotherapy without any significant hematological side effects, but after the 14th cycle, she developed melena and was admitted for severe thrombocytopenia. After supportive care, the platelet counts rapidly improved to 76,000/μL. Upon initiation of FOLFIRI and cetuximab chemotherapy, she again developed rectal bleeding and severe thrombocytopenia with a platelet count of 6000/μL. Lab testing was positive for oxaliplatin and irinotecan drug-dependent platelet antibodies on flow cytometry assay. Drug-induced thrombocytopenia (DITP) is associated with several classes of drugs with several proposed underlying mechanisms. Prospective studies are needed to further address different mechanisms of drug-induced thrombocytopenia.http://dx.doi.org/10.1155/2019/4314797 |
| spellingShingle | Eric L. Tam Padma L. Draksharam Jennifer A. Park Gurinder S. Sidhu Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy Case Reports in Oncological Medicine |
| title | Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy |
| title_full | Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy |
| title_fullStr | Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy |
| title_full_unstemmed | Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy |
| title_short | Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy |
| title_sort | acute immune mediated thrombocytopenia due to oxaliplatin and irinotecan therapy |
| url | http://dx.doi.org/10.1155/2019/4314797 |
| work_keys_str_mv | AT ericltam acuteimmunemediatedthrombocytopeniaduetooxaliplatinandirinotecantherapy AT padmaldraksharam acuteimmunemediatedthrombocytopeniaduetooxaliplatinandirinotecantherapy AT jenniferapark acuteimmunemediatedthrombocytopeniaduetooxaliplatinandirinotecantherapy AT gurinderssidhu acuteimmunemediatedthrombocytopeniaduetooxaliplatinandirinotecantherapy |